Cargando…
Content validation of the SF-36v2® Health Survey Acute for use in hypoparathyroidism
PURPOSE: The purpose of this study was to conduct cognitive debriefing (CD) interviews with adults diagnosed with chronic hypoparathyroidism (HP) to assess the content validity of the SF-36v2® Health Survey Acute (SF-36v2) measure in this population. METHODS: CD interviews were conducted with adults...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10172226/ https://www.ncbi.nlm.nih.gov/pubmed/36759379 http://dx.doi.org/10.1007/s11136-023-03352-x |
_version_ | 1785039577276219392 |
---|---|
author | Brod, Meryl Waldman, Laura Tesler Shu, Aimee D. Smith, Alden |
author_facet | Brod, Meryl Waldman, Laura Tesler Shu, Aimee D. Smith, Alden |
author_sort | Brod, Meryl |
collection | PubMed |
description | PURPOSE: The purpose of this study was to conduct cognitive debriefing (CD) interviews with adults diagnosed with chronic hypoparathyroidism (HP) to assess the content validity of the SF-36v2® Health Survey Acute (SF-36v2) measure in this population. METHODS: CD interviews were conducted with adults with HP in the United States (US). Interviews were conducted by a trained moderator using a semi-structured interview guide, employing a think-aloud method in conjunction with verbal probing. Participants were asked whether each item was understandable, relevant, important, and sensitive to change in relation to HP. Additionally, comprehension of instructions, response options, and the appropriateness of a 1-week recall period was assessed. RESULTS: Sixteen adults with HP participated in individual CD telephone interviews. All items in the SF-36v2 were reported to be understood, relevant, important, and sensitive to change by at least half, and in most cases, by a strong majority of study participants. Most of the study sample confirmed comprehension of the instructions and the entire sample understood all response options. CONCLUSION: The study findings show that the items in the SF-36v2® are applicable to adults with HP. The overall high levels of endorsement of items provide strong evidence of the measure’s content validity for this population. The SF-36v2 is therefore recommended for usage in clinical trials examining adults with HP, although it is recommended that this generic measure be supplemented with disease-specific instruments such as the recently developed Hypoparathyroidism Patient Experience Scale—Symptom (HPES-Symptom) and Hypoparathyroidism Patient Experience Scale—Impact (HPES-Impact) measures. |
format | Online Article Text |
id | pubmed-10172226 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-101722262023-05-12 Content validation of the SF-36v2® Health Survey Acute for use in hypoparathyroidism Brod, Meryl Waldman, Laura Tesler Shu, Aimee D. Smith, Alden Qual Life Res Article PURPOSE: The purpose of this study was to conduct cognitive debriefing (CD) interviews with adults diagnosed with chronic hypoparathyroidism (HP) to assess the content validity of the SF-36v2® Health Survey Acute (SF-36v2) measure in this population. METHODS: CD interviews were conducted with adults with HP in the United States (US). Interviews were conducted by a trained moderator using a semi-structured interview guide, employing a think-aloud method in conjunction with verbal probing. Participants were asked whether each item was understandable, relevant, important, and sensitive to change in relation to HP. Additionally, comprehension of instructions, response options, and the appropriateness of a 1-week recall period was assessed. RESULTS: Sixteen adults with HP participated in individual CD telephone interviews. All items in the SF-36v2 were reported to be understood, relevant, important, and sensitive to change by at least half, and in most cases, by a strong majority of study participants. Most of the study sample confirmed comprehension of the instructions and the entire sample understood all response options. CONCLUSION: The study findings show that the items in the SF-36v2® are applicable to adults with HP. The overall high levels of endorsement of items provide strong evidence of the measure’s content validity for this population. The SF-36v2 is therefore recommended for usage in clinical trials examining adults with HP, although it is recommended that this generic measure be supplemented with disease-specific instruments such as the recently developed Hypoparathyroidism Patient Experience Scale—Symptom (HPES-Symptom) and Hypoparathyroidism Patient Experience Scale—Impact (HPES-Impact) measures. Springer International Publishing 2023-02-09 2023 /pmc/articles/PMC10172226/ /pubmed/36759379 http://dx.doi.org/10.1007/s11136-023-03352-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/ Open Access Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Brod, Meryl Waldman, Laura Tesler Shu, Aimee D. Smith, Alden Content validation of the SF-36v2® Health Survey Acute for use in hypoparathyroidism |
title | Content validation of the SF-36v2® Health Survey Acute for use in hypoparathyroidism |
title_full | Content validation of the SF-36v2® Health Survey Acute for use in hypoparathyroidism |
title_fullStr | Content validation of the SF-36v2® Health Survey Acute for use in hypoparathyroidism |
title_full_unstemmed | Content validation of the SF-36v2® Health Survey Acute for use in hypoparathyroidism |
title_short | Content validation of the SF-36v2® Health Survey Acute for use in hypoparathyroidism |
title_sort | content validation of the sf-36v2® health survey acute for use in hypoparathyroidism |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10172226/ https://www.ncbi.nlm.nih.gov/pubmed/36759379 http://dx.doi.org/10.1007/s11136-023-03352-x |
work_keys_str_mv | AT brodmeryl contentvalidationofthesf36v2healthsurveyacuteforuseinhypoparathyroidism AT waldmanlauratesler contentvalidationofthesf36v2healthsurveyacuteforuseinhypoparathyroidism AT shuaimeed contentvalidationofthesf36v2healthsurveyacuteforuseinhypoparathyroidism AT smithalden contentvalidationofthesf36v2healthsurveyacuteforuseinhypoparathyroidism |